

Slovenia

Population 2015

2.1 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.016 (0.015–0.016)	0.75 (0.75–0.76)
Mortality (HIV+TB only)	<0.01 (<0.01–<0.01)	0 (0–0)
Incidence (includes HIV+TB)	0.15 (0.13–0.17)	7.2 (6.2–8.3)
Incidence (HIV+TB only)	0 (0–0)	0.01 (0–0.01)
Incidence (MDR/RR-TB)**	0 (0–0)	0 (0–0)

Estimated TB incidence by age and sex (thousands)*, 2015	Estimated TB incidence by age and sex (thousands)*, 2015		Total
	0-14 years	> 14 years	
Females	0 (0–<0.01)	0.053 (0.038–0.068)	0.053 (0.035–0.071)
Males	0.01 (<0.01–0.013)	0.085 (0.067–0.1)	0.095 (0.074–0.12)
Total	0.01 (<0.01–0.013)	0.14 (0.13–0.15)	0.15 (0.13–0.17)

TB case notifications, 2015	
Total cases notified	130
Total new and relapse	129
- % tested with rapid diagnostics at time of diagnosis	54%
- % with known HIV status	83%
- % pulmonary	77%
- % bacteriologically confirmed among pulmonary	96%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.11 (0.09–0.12)

TB/HIV care in new and relapse TB patients, 2015	Number	(%)
Patients with known HIV-status who are HIV-positive	0	0%
- on antiretroviral therapy	0	

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			0 (0–0)
Estimated % of TB cases with MDR/RR-TB	0% (0–4.1)	0% (0–41)	
% notified tested for rifampicin resistance	93%	70%	119
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 0, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 0, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	77%	142
Previously treated cases, excluding relapse, registered in 2014	50%	2
HIV-positive TB cases, all types, registered in 2014		0
MDR/RR-TB cases started on second-line treatment in 2013		
XDR-TB cases started on second-line treatment in 2013		

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)



— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB